Document Detail


Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status.
MedLine Citation:
PMID:  23299279     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Cytoreductive nephrectomy (CN) plays an important role in the multimodal treatment of metastatic renal cell carcinoma (RCC). However, certain patients experience rapid progression of the carcinoma following CN. This study aimed to investigate the value of neutrophil-to-lymphocyte ratio (NLR) in the selection of patients for CN. METHODS: Records corresponding to 73 patients with metastatic RCC were retrospectively reviewed. Forty-eight patients underwent CN, and their overall survival (OS) and preoperative variables were analyzed. The OS of patients who did not undergo CN was used as a reference. RESULTS: Univariate analysis showed that symptomatic tumors, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≥1, hemoglobin level <12 g/dl, neutrophil count ≥5500/μL, C-reactive protein level ≥2.0 mg/dl, and NLR ≥4.0 were significantly associated with poor outcomes in patients who underwent cytoreductive nephrectomy. The median OS of patients with NLR ≥4.0 was 10.2 months, which was significantly shorter than that of patients with NLR <4.0 (36.5 months) (P = 0.0020). Multivariate analysis showed that NLR and ECOG-PS were independent predictors of OS in patients treated with CN. The OS of CN patients with NLR ≥4.0 and ECOG-PS ≥1 was similar to that of patients who did not undergo CN (8.4 vs. 6.1 months, P = 0.939). CONCLUSIONS: Preoperative NLR elevation is significantly associated with poor outcomes in patients with metastatic RCC who underwent CN. Patients with NLR ≥4.0 and ECOG-PS ≥1 might not benefit from immediate CN after initial diagnosis.
Authors:
Yoshio Ohno; Jun Nakashima; Makoto Ohori; Ayako Tanaka; Takeshi Hashimoto; Tatsuo Gondo; Tadashi Hatano; Masaaki Tachibana
Related Documents :
23885139 - Mir-20b, mir-98, mir-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulc...
23417759 - Efficacy and safety of deferasirox in myelodysplastic syndromes.
24991149 - Case-control study of error-related negativity among males with heroin dependence under...
22955029 - State of intracortical inhibitory interneuron activity in patients with chronic stroke.
23661909 - A comparison of cognitive functions in non-hypoxemic chronic obstructive pulmonary dise...
24372959 - Serum albumin level as a predictor of intensive respiratory or vasopressor support in i...
7775959 - Follow-up of antibody responses to human papillomavirus type 16 e7 in patients treated ...
23885139 - Mir-20b, mir-98, mir-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulc...
8212999 - Phase ii study of recombinant human granulocyte-macrophage colony-stimulating factor in...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-9
Journal Detail:
Title:  International journal of clinical oncology     Volume:  -     ISSN:  1437-7772     ISO Abbreviation:  Int. J. Clin. Oncol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9616295     Medline TA:  Int J Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Urology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 1600023, Japan, yoshio-o@tokyo-med.ac.jp.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patient...
Next Document:  Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma ...